These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8247304)

  • 1. [Monitoring of heparin therapy].
    Camici M; Evangelisti L
    Minerva Med; 1993 Oct; 84(10):507-9. PubMed ID: 8247304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
    Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
    Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
    Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
    Eikelboom JW; Hirsh J
    Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the value of the activated partial thrombo-plastin time (aptt) in monitoring heparin therapy.
    Teien AN; Abildgaard U
    Thromb Haemost; 1976 Jun; 35(3):592-7. PubMed ID: 989966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays.
    Fey MF; Lang M; Furlan M; Beck EA
    Thromb Haemost; 1987 Oct; 58(3):853-5. PubMed ID: 3481140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modification of the global coagulation tests for the dog. Significance for the monitoring of heparin therapy].
    Mischke R; Nolte I
    Tierarztl Prax; 1991 Oct; 19(5):561-6. PubMed ID: 1759273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current considerations in the use of the APTT in monitoring unfractionated heparin.
    Nelson DE
    Clin Lab Sci; 1999; 12(6):359-64. PubMed ID: 10724634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical safety and cost of heparin titration using bedside activated clotting time.
    Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M
    Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy.
    Racioppi L; Quinart A; Biais M; Nouette-Gaulain K; Revel P; Sztark F
    Anaesthesia; 2009 Apr; 64(4):430-4. PubMed ID: 19317710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area].
    Tanaka N; Manabe M; Yamashita S; Ikeda K; Obayashi K; Uchiba M; Ando Y
    Rinsho Byori; 2013 Jul; 61(7):576-82. PubMed ID: 24205697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic heparin monitoring service in a small community hospital.
    Pawloski SJ; Kersh PL
    Hosp Pharm; 1992 Aug; 27(8):703-6, 723. PubMed ID: 10119735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.